$NSPR
InspireMD, Inc. Stock $nspr

$nspr Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044578 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$1.810M
YoY Change		16.32%
Cost Of Revenue		$1.396M
YoY Change		24.87%
Gross Profit		$414.0K
YoY Change		-5.48%
Gross Profit Margin		22.87%
Selling, General & Admin		$4.961M
YoY Change		25.06%
% of Gross Profit		1198.31%
Research & Development		$3.915M
YoY Change		85.55%
% of Gross Profit		945.65%
Depreciation & Amortization		$70.00K
YoY Change		14.75%
% of Gross Profit		16.91%
Operating Expenses		$8.876M
YoY Change		46.06%
Operating Profit		-$8.462M
YoY Change		50.06%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$572.0K
YoY Change		24.08%
Pretax Income		-$7.890M
YoY Change		52.38%
Income Tax
% Of Pretax Income
Net Earnings		-$7.890M
YoY Change		52.38%
Net Earnings / Revenue		-435.91%
Basic Earnings Per Share		-$0.16
Diluted Earnings Per Share		-$0.16
COMMON SHARES
Basic Shares Outstanding	26.08M shares	25.71M shares
Diluted Shares Outstanding		48.37M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$40.40M
YoY Change		-6.04%
Cash & Equivalents		$15.82M
Short-Term Investments		$24.58M
Other Short-Term Assets		$1.276M
YoY Change		168.07%
Inventory		$2.445M
Prepaid Expenses		$1.276M
Receivables		$1.530M
Other Receivables		$741.0K
Total Short-Term Assets		$46.39M
YoY Change		-0.71%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.946M
YoY Change		114.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$996.0K
YoY Change		17.59%
Total Long-Term Assets		$4.087M
YoY Change		24.15%
TOTAL ASSETS
Total Short-Term Assets		$46.39M
Total Long-Term Assets		$4.087M
Total Assets		$50.48M
YoY Change		0.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.305M
YoY Change		117.5%
Accrued Expenses		$1.437M
YoY Change		55.18%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$7.265M
YoY Change		54.9%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$1.865M
YoY Change		-10.03%
Total Long-Term Liabilities		$1.865M
YoY Change		-10.03%
TOTAL LIABILITIES
Total Short-Term Liabilities		$7.265M
Total Long-Term Liabilities		$1.865M
Total Liabilities		$9.130M
YoY Change		35.0%
SHAREHOLDERS EQUITY
Retained Earnings		-$244.3M
YoY Change		13.07%
Common Stock		$3.000K
YoY Change		50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$41.35M
YoY Change
Total Liabilities & Shareholders Equity		$50.48M
YoY Change		0.92%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$7.890M
YoY Change		52.38%
Depreciation, Depletion And Amortization		$70.00K
YoY Change		14.75%
Cash From Operating Activities		-$5.700M
YoY Change		41.12%
INVESTING ACTIVITIES
Capital Expenditures		$421.0K
YoY Change		338.54%
Acquisitions
YoY Change
Other Investing Activities		-$5.503M
YoY Change		-184.92%
Cash From Investing Activities		-$5.924M
YoY Change		-192.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-965.0K
YoY Change		-24225.0%
NET CHANGE
Cash From Operating Activities		-5.700M
Cash From Investing Activities		-5.924M
Cash From Financing Activities		-965.0K
Net Change In Cash		-12.59M
YoY Change		-635.93%
FREE CASH FLOW
Cash From Operating Activities		-$5.700M
Capital Expenditures		$421.0K
Free Cash Flow		-$6.121M
YoY Change		48.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001433607
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35731
	dei	Entity Registrant Name EntityRegistrantName	InspireMD, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2123838
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6303 Waterford District Drive
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15818000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9640000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	24584000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	44159000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1946000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1060000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1145000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1473000	usd
CY2024Q3	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	996000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	951000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	4087000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3484000	usd
CY2024Q3	us-gaap	Assets Assets	50481000	usd
CY2023Q4	us-gaap	Assets Assets	47643000	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1305000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	939000	usd
CY2024Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5960000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7265000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6020000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	682000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038000	usd
CY2024Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1183000	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1084000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1865000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2122000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	9130000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8142000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25719632	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25719632	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21841215	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21841215	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	3000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4444000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4023000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3142000	usd
	us-gaap	Gross Profit GrossProfit	1037000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9941000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5946000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4154000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2556000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8135000	usd
	us-gaap	Operating Expenses OperatingExpenses	25173000	usd
	us-gaap	Operating Expenses OperatingExpenses	16637000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24136000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15335000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1305000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	824000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-72000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9207000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4632000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13839000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1810000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1556000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5060000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4444000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	NSPR	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		usd
CY2024Q3	NSPR	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits		usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	NSPR	Proceeds From Matured Marketable Securities ProceedsFromMaturedMarketableSecurities		usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
	NSPR	Noncash Acquisition Of Right Of Use Assets By Means Of Lease Liabilities NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities		usd
	NSPR	Noncash Lease Incentive NoncashLeaseIncentive		usd
	NSPR	Decrease In Rightofuse Assets And Lease Liabilities Due To Shortening Lease Term DecreaseInRightofuseAssetsAndLeaseLiabilitiesDueToShorteningLeaseTerm		usd
CY2024Q3	NSPR	Marketable Securities Maturities After One Year Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 215
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33126
	dei	City Area Code CityAreaCode	(888)
	dei	Local Phone Number LocalPhoneNumber	776-6804
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	NSPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26083763	shares
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1530000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1804000	usd
CY2024Q3	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	741000	usd
CY2023Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	648000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1276000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	578000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	2445000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	46394000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	285680000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	261000000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244332000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-221501000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	41351000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39501000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50481000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47643000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1810000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1556000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5060000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1396000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1118000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	414000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	438000	usd
	us-gaap	Gross Profit GrossProfit	1302000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3915000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2110000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1472000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	876000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3489000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3091000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11078000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	8876000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	6077000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8462000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5639000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	572000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	461000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7890000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5178000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14511000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48369412	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48369412	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33984953	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33984953	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39413004	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39413004	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21148538	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21148538	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14511000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	14019	shares
	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	2841000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	43257000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-5178000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	9749	shares
CY2023Q3	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	1622000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	43257000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	39501000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	12621090	shares
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	usd
	NSPR	Stock Issued During Period Value Stock Warrants Exercised And Common Stock StockIssuedDuringPeriodValueStockWarrantsExercisedAndCommonStock	16854000	usd
	NSPR	Stock Issued During Period Value Stock Warrants Exercised And Common Stock StockIssuedDuringPeriodValueStockWarrantsExercisedAndCommonStock	16854000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	35000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	112382	shares
	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	7792000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	41351000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46763000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	46763000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-7890000	usd
CY2024Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	35000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	35000	usd
CY2024Q3	NSPR	Sharebased Compensation Related To Restricted Stock Restricted Stock Units And Stock Options Award Net Of Forfeitures SharebasedCompensationRelatedToRestrictedStockRestrictedStockUnitsAndStockOptionsAwardNetOfForfeitures	2443000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	41351000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	41351000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-22831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14511000	usd
	us-gaap	Depreciation Depreciation	205000	usd
	us-gaap	Depreciation Depreciation	171000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	4000	usd
	NSPR	Loss Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	-21000	usd
	NSPR	Loss Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	-70000	usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	757000	usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	321000	usd
	NSPR	Change In Liability For Employees Rights Upon Retirement ChangeInLiabilityForEmployeesRightsUponRetirement	-99000	usd
	NSPR	Change In Liability For Employees Rights Upon Retirement ChangeInLiabilityForEmployeesRightsUponRetirement	-16000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	8000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-72000	usd
	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	39000	usd
	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	39000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7792000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2841000	usd
	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	-171000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	698000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-179000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-274000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	93000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	150000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	339000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	225000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	366000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-59000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	890000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-399000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15118000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12199000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1091000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	166000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14444000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28838000	usd
	NSPR	Proceeds From Matured Marketable Securities ProceedsFromMaturedMarketableSecurities	20000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	18500000	usd
	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	66000	usd
	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	61000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4399000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16056000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1000000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1000000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	16854000	usd
	NSPR	Proceeds From Issuance Of Shares And Warrants Net ProceedsFromIssuanceOfSharesAndWarrantsNet	35000	usd
	NSPR	Proceeds From Issuance Of Shares And Warrants Net ProceedsFromIssuanceOfSharesAndWarrantsNet	37534000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16889000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37534000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6178000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9640000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15818000	usd
	NSPR	Noncash Acquisition Of Right Of Use Assets By Means Of Lease Liabilities NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities	419000	usd
	NSPR	Noncash Lease Incentive NoncashLeaseIncentive	45000	usd
	NSPR	Decrease In Rightofuse Assets And Lease Liabilities Due To Shortening Lease Term DecreaseInRightofuseAssetsAndLeaseLiabilitiesDueToShorteningLeaseTerm	131000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_807_eus-gaap--NatureOfOperations_zpcr0FxRqMmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82B_zhMg9Gxk7nYh">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company markets its products through distributors in international markets, mainly in Europe.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b</b>.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit as of September 30, 2024, as well as a history of net losses and negative operating cash flows in recent years. The Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. As a result of these expected losses and negative cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient resources to fund operations for at least the next 12 months. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management’s plans include the continued commercialization of the Company’s product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships and exercise of warrants. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it may need to reduce activities, curtail or cease operations.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Company’s Operations in Israel </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization), Israel’s southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The Company operations, including its production facility, are located in Israel. Currently, such activities in Israel remain largely unaffected.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine and three months ended September 30, 2024, the impact of this war on the Company’s results of operations and financial condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion of such war.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_804_eus-gaap--BasisOfAccounting_znXicKj3Qltl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_820_zZI7Fkugun9j">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements for the year ended December 31, 2023. In the opinion of the company, all adjustments considered necessary for a fair statement of the results of the interim periods reported herein have been included (consisting only of normal recurring adjustments). These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 5, 2024. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of results that could be expected for the entire fiscal year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Securities Borrowed Fair Value Disclosure SecuritiesBorrowedFairValueDisclosure	23919000	usd
CY2023Q4	us-gaap	Securities Borrowed Fair Value Disclosure SecuritiesBorrowedFairValueDisclosure	28727000	usd
CY2024Q3	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue	24584000	usd
CY2023Q4	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue	24523000	usd
CY2023Q4	NSPR	Marketable Securities Maturities After One Year Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneYearThroughTwoYearsFairValue	4860000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	24584000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29383000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14444000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28838000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20000000	usd
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	217000	usd
	NSPR	Changes In Fair Value Marketable Securities ChangesInFairValueMarketableSecurities	974000	usd
	NSPR	Changes In Fair Value Marketable Securities ChangesInFairValueMarketableSecurities	321000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	24584000	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	29159000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40268464	shares
	NSPR	Class Of Warrants Expired ClassOfWarrantsExpired	213458000	shares
CY2024Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	155000000	shares
CY2024Q3	NSPR	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	19016286	shares
CY2024Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	26199497	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3979486	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3073821	shares
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	68000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	210000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	557000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	562000	usd
CY2024Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1820000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1334000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	2445000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2106000	usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2312000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2188000	usd
CY2024Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	401000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	287000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1437000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1115000	usd
CY2024Q3	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1078000	usd
CY2023Q4	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	744000	usd
CY2024Q3	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	546000	usd
CY2023Q4	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	557000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	186000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	190000	usd
CY2024Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5960000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-044578-index-headers.html	Edgar Link	pending
0001493152-24-044578-index.html	Edgar Link	pending
0001493152-24-044578.txt	Edgar Link	pending
0001493152-24-044578-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nspr-20240930.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nspr-20240930_cal.xml	Edgar Link	unprocessable
nspr-20240930_def.xml	Edgar Link	unprocessable
nspr-20240930_lab.xml	Edgar Link	unprocessable
nspr-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NSPR
InspireMD, Inc. Stock $nspr

2024 Q4 Form 10-Q Financial Statement

#000149315224044578 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR InspireMD, Inc. Stock $nspr

2024 Q4 Form 10-Q Financial Statement

#000149315224044578 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR
InspireMD, Inc. Stock $nspr